Agios Pharmaceuticals vs Precigen
AGIO and PGEN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AGIO and PGEN compare
Agios Pharmaceuticals is the larger company, worth 1.2 times as much as Precigen ($1.9B against $1.6B).
Precigen keeps more of each dollar of sales as profit, with a net margin of 15.6% compared with −265% at Agios Pharmaceuticals.
Agios Pharmaceuticals scores higher on the StockData Score (13 against 6 for Precigen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AGIO | PGEN |
|---|---|---|
| Size and price | ||
| Market cap | $1.9B | $1.6B |
| Share price | $31.59 | $4.54 |
| Change, 1 year | −27.6% | 12.9% |
| Change, 5 years | −17.3% | 20.7% |
| Beta (5Y) | 1.41 | 1.63 |
| Employees | 539 | 20 |
| StockData Score | ||
| Total score | 13 (better) | 6 |
| Valuation score | 2 (better) | 0 |
| Growth score | 3 (better) | 0 |
| Performance score | 2 | 4 (better) |
| Health score | 6 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 114× |
| P/S | 13.4× | 10.4× (better) |
| P/B | 1.9× (better) | 19.4× |
| EV/EBITDA | – | 43.8× |
| FCF yield | −17.8% | −4.6% (better) |
| Fair value | $32.10 | $1.34 |
| Margin of safety | 1.6% (better) | −239% |
| Growth | ||
| Revenue growth (TTM) | 214% | – |
| Revenue growth, 5Y average | – | −21.3% |
| Profitability | ||
| Gross margin | 93.8% | – |
| Operating margin | −298% | 21.4% (better) |
| Net margin | −265% | 15.6% (better) |
| FCF margin | −239% | −47.4% (better) |
| Return on equity | −32.9% | 38.8% (better) |
| Return on invested capital | −1169% | 147% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 1.12 (better) |
| Net debt / EBITDA | – | 1.14 |
| Interest coverage | – | 2.8× |
| Current ratio | 9.69 (better) | 5.58 |
| Altman Z-score | 11.86 (better) | −5.48 |
| Piotroski F-score | 1 | 2 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 0.00% |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 111% | 39.2% |
| Held by insiders | 1.1% | 44.9% |
| Insider net buying, 12 months | −$4.9M (better) | −$32.5M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 11.1% | 22.8% |
Go deeper
- AGIO stock overview
- AGIO income statement
- AGIO valuation and score
- PGEN stock overview
- PGEN income statement
- PGEN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.